TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Sees Large Decrease in Short Interest

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) saw a significant drop in short interest in November. As of November 30th, there was short interest totalling 19,100 shares, a drop of 50.1% from the November 15th total of 38,300 shares. Based on an average daily trading volume, of 1,140,000 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright decreased their price target on shares of TC Biopharm from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday, December 6th.

TC Biopharm Trading Down 9.4 %

Shares of NASDAQ TCBP traded down $0.05 during mid-day trading on Friday, hitting $0.53. The company’s stock had a trading volume of 337,796 shares, compared to its average volume of 499,384. The company has a quick ratio of 0.88, a current ratio of 1.12 and a debt-to-equity ratio of 0.67. The company’s fifty day simple moving average is $1.85 and its 200-day simple moving average is $5.35. TC Biopharm has a one year low of $0.44 and a one year high of $41.50.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.